Canada´s new measures to ensure the supply of COVID-19 vaccines

The federal government is working closely with researchers and scientists to better understand the virus and protect the health of Canadians. This week the Prime Minister, Justin Trudeau, announced that agreements in principle have been reached with Johnson & Johnson and Novavax to procure millions of doses of experimental COVID 19 vaccines. These agreements add to those already reached with Pfizer and Moderna, which were made following the recommendations of the COVID-19 Vaccine Task Force.

The Prime Minister also announced funding to establish a new biomanufacturing facility at the Human Health Therapeutics Research Centre in Montréal. Through a public-private partnership, the new building will enable the National Research Council of Canada (NRC) to increase vaccine manufacturing to up to two million doses per month by next year, said Primer Minister Office in a press release.

Specifically, the government of Canada will invest $126 million over two years to build the new facility. “As we continue to work together to limit the impact of the COVID-19 pandemic on the health of Canadians, we must also maximize our chances of defeating the virus. To do this, we need to invest in the development of several promising vaccines and ensure that we can manufacture and distribute the vaccine to as many Canadians as possible, as quickly as possible”, stated Prime Minister Trudeau.